Dhindsa Devinder S, Sandesara Pratik B, Shapiro Michael D
Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States.
Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, United States.
Front Cardiovasc Med. 2018 Nov 13;5:160. doi: 10.3389/fcvm.2018.00160. eCollection 2018.
Diabetes is a leading cause of cardiovascular disease and its associated morbidity. While the medical community has had access to numerous glucose lowering therapies over the last decades, it was not until recently that newer agents demonstrated improvement in cardiovascular outcomes. In particular, diabetes care and management of its attendant cardiovascular risk is now being revolutionized with the development and provision of the SGLT-2 inhibitors and GLP1-receptor agonists. Given the exciting data with these new classes of diabetes therapeutics, there is a clear need to improve education and utilization of these evidence-based medications across a wide spectrum of clinicians, including cardiologists. The aim of this review is to familiarize the cardiovascular specialist with the benefits and harms of the most commonly used oral anti- hyperglycemic medications, with an emphasis on SGLT-2 inhibitors and GLP-1 receptor agonists.
糖尿病是心血管疾病及其相关发病率的主要原因。在过去几十年里，医学界已有多种降糖疗法可供使用，但直到最近，新型药物才显示出心血管结局有所改善。特别是，随着SGLT-2抑制剂和GLP-1受体激动剂的研发和应用，糖尿病护理及其伴随的心血管风险的管理正在发生变革。鉴于这些新型糖尿病治疗药物的令人振奋的数据，显然有必要在包括心脏病专家在内的广泛临床医生中加强对这些循证药物的教育和使用。本综述的目的是让心血管专科医生熟悉最常用的口服抗高血糖药物的益处和危害，重点是SGLT-2抑制剂和GLP-1受体激动剂。
